Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
SAP30 promotes breast tumor progression by bridging the transcriptional corepressor SIN3 complex and MLL1
Lei Bao, … , Yingfei Wang, Weibo Luo
Lei Bao, … , Yingfei Wang, Weibo Luo
Published September 1, 2023
Citation Information: J Clin Invest. 2023;133(17):e168362. https://doi.org/10.1172/JCI168362.
View: Text | PDF
Research Article Oncology

SAP30 promotes breast tumor progression by bridging the transcriptional corepressor SIN3 complex and MLL1

  • Text
  • PDF
Abstract

SAP30 is a core subunit of the transcriptional corepressor SIN3 complex, but little is known about its role in gene regulation and human cancer. Here, we show that SAP30 was a nonmutational oncoprotein upregulated in more than 50% of human breast tumors and correlated with unfavorable outcomes in patients with breast cancer. In various breast cancer mouse models, we found that SAP30 promoted tumor growth and metastasis through its interaction with SIN3A/3B. Surprisingly, the canonical gene silencing role was not essential for SAP30’s tumor-promoting actions. SAP30 enhanced chromatin accessibility and RNA polymerase II occupancy at promoters in breast cancer cells, acting as a coactivator for genes involved in cell motility, angiogenesis, and lymphangiogenesis, thereby driving tumor progression. Notably, SAP30 formed a homodimer with 1 subunit binding to SIN3A and another subunit recruiting MLL1 through specific Phe186/200 residues within its transactivation domain. MLL1 was required for SAP30-mediated transcriptional coactivation and breast tumor progression. Collectively, our findings reveal that SAP30 represents a transcriptional dependency in breast cancer.

Authors

Lei Bao, Ashwani Kumar, Ming Zhu, Yan Peng, Chao Xing, Jennifer E. Wang, Yingfei Wang, Weibo Luo

×

Figure 9

MLL1 binds the transactivation domain of SAP30.

Options: View larger image (or click on image) Download as PowerPoint
MLL1 binds the transactivation domain of SAP30.
(A) Predicted SAP30 tran...
(A) Predicted SAP30 transactivation domain. The key hydrophobic residues for transactivation activity are highlighted in yellow. (B) Gal4 luciferase reporter assay in HEK293T cells transfected with indicated plasmids (mean ± SEM, n = 3). ****P < 0.0001 by 1-way ANOVA with Tukey’s test. (C) Co-IP assay showing that MLL1 interacts with SAP30 and SIN3A in MDA-MB-231 cells (n = 2). (D) Co-IP assay showing that MLL1 binds F186/F200 residues of SAP30 in MDA-MB-231 cells (n = 3). (E) Co-IP assay showing that SIN3A/3B DKO increases MLL1-SAP30 interaction in MDA-MB-231 cells (n = 2). SIN3A and SIN3B blots were run in parallel using the same biological samples. (F and G) Coomassie staining and immunoblot of purified human SAP30 (F, n = 3) and SIN3A (G, n = 2) protein treated with or without β-mercaptoethanol (β-ME) and boiling.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts